Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ION 859

Next Previous
Drug Profile

ION 859

Alternative Names: BIIB-094; ION859; IONIS-BIIB7Rx

Latest Information Update: 05 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen
  • Developer Biogen; Ionis Pharmaceuticals
  • Class Antiparkinsonians; Antisense oligonucleotides
  • Mechanism of Action LRRK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 05 Apr 2025 Pharmacodynamics, pharmacokinetics and adverse events data from a phase I/II trial in Parkinson's disease presented at the American Academy of Dermatology annual Meeting 2025 (AAD-2025)
  • 12 Aug 2024 Biogen completed the phase II trial in Parkinson's disease in Norway (Intrathecal), after August 2019 (NCT03976349)
  • 25 Jul 2022 ION 859 is still in phase II trial for Parkinson's disease in USA, Canada, Israel, Spain, Norway and United Kingdom (Intrathecal) (NCT03976349)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top